Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Cardiovascular Diseases Clinical Trial

Official title:

ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00153101
• Other study ID #: 502.373
• Status: Completed
• Phase: Phase 4
• First received: September 9, 2005
• Last updated: May 13, 2014
• Start date: November 2001

Study information

• Verified date: May 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Argentina: National Administration of Medicines, Food and Medical TechnologyAustralia: Responsilble Ethics CommitteeAustria: Ministry for Social Security and GenerationsBelgium: Federal Agency for Medicines and Health Products, FAMHPBrazil: National Health Surveillance AgencyCanada: Health CanadaChina: Food and Drug AdministrationCzech Republic: State Institute for Drug Control (SUKL)Denmark: Danish Medicines AgencyFinland: Finnish Medicines AgencyFrance: AFFSAPSGermany: Federal Institute for Drugs and Medical DevicesGreat Britain: MHRAGreece: HELLENIC REPUBLIC MINISTRY OF HEALTH AND WELFARE NATIONAL ORGANISATION OF MEDICINES (EOF)Hong Kong: Dept. of Health, Hong KongHungary: National Institute of Pharmacy (OGYI), H-1051 BudapestIreland: The Irish Medicines BoardItaly: Comitato Etico delle Aziende Sanitarie della Regione UmbriaKorea, Republic of: Korea Food and Drug Administration (KFDA)Malaysia: Drug Control AuthorityMexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)New Zealand: Multicentre Ethics Committee/MedsafeNorway: Norwegian Medicines Agency (Statens Legemiddelverk)Philippines: Bureau of Pharmaceutical Affairs, Department of HealthPoland: CEBK, WarsawPortugal: INFARMED, National Authority of Medicines and Health Products, IPRussia: Ministry of Health of the Russian FederationSingapore: Centre of Drug AdministrationSlovakia: SUKL (state institute for drug control), SK-825 08 Bratislava 26South Africa: Medicines Control CouncilSpain: Ministry of HealthSweden: Medical Product AgencySwitzerland: Swissmedic Schweizerisches Heilmittelinstitut (Swiss Agency for Therapeutic Products)Taiwan: Dept. of Health, Executive Yuan, TaiwanThailand: Bureau of Pharmaceutical Affairs, Department of HealthTurkey: Ministry of Health Central Ethics CommitteeUkraine: State Pharmacology Centre of the Ministry of Health of UkraineUnited Arab. Emirates: Medical Affairs Department of Health and Medical Services, General Authority Health Services, Ministry of Health for Northern EmiratesUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.

Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.

Other known NCT identifiers

• NCT00034931

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31546
• Est. primary completion date: June 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

Coronary Artery Disease: Previous Myocardial infarction(> 2 days prior to informed consent), or stable or previous unstable angina (> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed > 4 years prior to informed consent) or with recurrent angina after surgery.

Other High Risk:

1. Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio < 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing

2. Previous stroke

3. Transient ischemic Attack > 7 days and < 1 year prior to informed consent

4. Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.

No definite and specific indication or contraindication for any of the study treatments. Written informed consent.

Exclusion Criteria:

A. Medication use:

1. Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).

2. Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.

NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.

B. Cardiovascular disease:

1. Symptomatic congestive heart failure.

2. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).

3. Constrictive pericarditis.

4. Complex congenital heart disease.

5. Syncopal episodes of unknown etiology < 3 months before informed consent.

6. Planned cardiac surgery or angioplasty within three months.

7. Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) > 160/100).

8. Heart transplant recipient.

9. Strokes due to subarachnoid hemorrhage

C. Other conditions:

1. Significant renal disease defined as:

1. Renal artery stenosis;

2. Creatinine clearance < 0.6 ml/min or serum creatinine > 265 umol/L (> 3.0 mg/dL);

3. Hyperkalemia: potassium > 5.5 mmol/L.

4. Proteinuria* (for TRANSCEND only).

2. Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) > than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin > 20 umol/L, biliary obstructive disorders.

3. Uncorrected volume depletion or sodium depletion.

4. Primary aldosteronism.

5. Hereditary fructose intolerance.

6. Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.

7. Patient is simultaneously taking another experimental drug.

8. Patient with significant disability that precludes regular attendance at clinic for follow-up.

9. Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.

10. Unable or unwilling to provide written informed consent.

Study Design

Intervention Model: Parallel Assignment, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Cardiovascular Diseases

Intervention

Drug:
• Telmisartan

• Combination of Telmisartan and Ramipril

• Ramipril

Locations

Country	Name	City	State
Argentina	502.373.350 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.351 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.352 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.353 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.354 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.355 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.356 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.378 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	502.373.357 Boehringer Ingelheim Investigational Site	Córdoba
Argentina	502.373.358 Boehringer Ingelheim Investigational Site	Córdoba
Argentina	502.373.360 Boehringer Ingelheim Investigational Site	Córdoba
Argentina	502.373.361 Boehringer Ingelheim Investigational Site	Córdoba
Argentina	502.373.377 Boehringer Ingelheim Investigational Site	Córdoba
Argentina	502.373.362 Boehringer Ingelheim Investigational Site	Corones Suárez
Argentina	502.373.364 Boehringer Ingelheim Investigational Site	La Plata
Argentina	502.373.365 Boehringer Ingelheim Investigational Site	Mar del Plata
Argentina	502.373.366 Boehringer Ingelheim Investigational Site	Mendoza
Argentina	502.373.376 Boehringer Ingelheim Investigational Site	Mendoza
Argentina	502.373.367 Boehringer Ingelheim Investigational Site	Rosario
Argentina	502.373.369 Boehringer Ingelheim Investigational Site	Salta
Argentina	502.373.375 Boehringer Ingelheim Investigational Site	Santa Fe
Argentina	502.373.371 Boehringer Ingelheim Investigational Site	Tucumán
Argentina	502.373.373 Boehringer Ingelheim Investigational Site	Tucumán
Argentina	502.373.374 Boehringer Ingelheim Investigational Site	Zárate
Australia	502.373.0546 Flinders Medical Centre	Bedford Park	South Australia
Australia	502.373.0531 Box Hill Hospital	Box Hill	Victoria
Australia	502.373.0536 Royal Prince Alfred Hospital	Camperdown	New South Wales
Australia	502.373.0523 The Prince Charles Hospital	Chermside	Queensland
Australia	502.373.0544 Coffs Harbour Cardiovascular Clinic	Coffs Harbour	New South Wales
Australia	502.373.0538 Concord Repatriation General Hospital	Concord	New South Wales
Australia	502.373.0550 Repatriation General Hospital	Daw Park	South Australia
Australia	502.373.0548 The Northern Hospital	Epping	Victoria
Australia	502.373.0547 Fremantle Hospital	Fremantle	Western Australia
Australia	502.373.0522 The Geelong Hospital	Geelong	Victoria
Australia	502.373.0539 Central Coast Neuroscience Research	Gosford	New South Wales
Australia	502.373.0556 Gosford Hospital	Gosford	New South Wales
Australia	502.373.0524 Royal Brisbane Hospital	Herston	Queensland
Australia	502.373.0526 Peninsula Clinical Research Centre	Kippa-Ring	Queensland
Australia	502.373.0542 St. George Hospital	Kogarah	New South Wales
Australia	502.373.0552 St George Private Hospital	Kogarah	New South Wales
Australia	502.373.0559 St George Hospital - Dept of Clinical Pharmacology	Kogarah	New South Wales
Australia	502.373.0529 Launceston General Hospital	Launceston	Tasmania
Australia	502.373.0530 Sir Charles Gairdner Hospital	Nedlands	Western Australia
Australia	502.373.0528 John Hunter Hospital	Newcastle	New South Wales
Australia	502.373.0520 Royal Melbourne Hospital	Parkville	Victoria
Australia	502.373.0545 Royal Perth Hospital	Perth	Western Australia
Australia	502.373.0551 Port Lincoln "The Investigator" Clinic	Port Lincoln	South Australia
Australia	502.373.0525 The Alfred Hospital	Prahran	Victoria
Australia	502.373.0532 Baker Medical Research Centre	Prahran	Victoria
Australia	502.373.0535 The Prince of Wales Hospital	Randwick	New South Wales
Australia	502.373.0557 Maroondah Hospital	Ringwood East	Victoria
Australia	502.373.0540 Gold Coast Hospital	Southport	Queensland
Australia	502.373.0533 Royal North Shore Hospital	St Leonards	New South Wales
Australia	502.373.0537 Austin & Repatriation Medical Centre	West Heidelberg	Victoria
Australia	502.373.0534 The Canberra Hospital	Woden	Australian Capital Territory
Australia	502.373.0549 Illawarra Regional Hospital	Wollongong	New South Wales
Australia	502.373.0521 Princess Alexandra Hospital	Woolloongabba	Queensland
Austria	502.373.1128 Boehringer Ingelheim Investigational Site	Graz
Austria	502.373.1125 Boehringer Ingelheim Investigational Site	Wels
Austria	502.373.1126 Boehringer Ingelheim Investigational Site	Wien
Austria	502.373.1127 Boehringer Ingelheim Investigational Site	Wien
Austria	502.373.1129 Boehringer Ingelheim Investigational Site	Wien
Belgium	502.373.1004 Boehringer Ingelheim Investigational Site	Aalst
Belgium	502.373.1015 Boehringer Ingelheim Investigational Site	Anderlecht
Belgium	502.373.1005 Boehringer Ingelheim Investigational Site	Antwerpen
Belgium	502.373.1022 Boehringer Ingelheim Investigational Site	Bornem
Belgium	502.373.1021 Boehringer Ingelheim Investigational Site	Brasschaat
Belgium	502.373.1003 Boehringer Ingelheim Investigational Site	Brugge
Belgium	502.373.1017 Boehringer Ingelheim Investigational Site	Charleroi
Belgium	502.373.1009 Boehringer Ingelheim Investigational Site	Genk
Belgium	502.373.1018 Boehringer Ingelheim Investigational Site	Godinne
Belgium	502.373.1011 Boehringer Ingelheim Investigational Site	Haine-Saint-Paul
Belgium	502.373.1019 Boehringer Ingelheim Investigational Site	Haine-Saint-Paul
Belgium	502.373.1007 Boehringer Ingelheim Investigational Site	Hasselt
Belgium	502.373.1000 Boehringer Ingelheim Investigational Site	Leuven
Belgium	502.373.1020 Boehringer Ingelheim Investigational Site	Mechelen
Belgium	502.373.1006 Boehringer Ingelheim Investigational Site	Mol
Belgium	502.373.1028 Boehringer Ingelheim Investigational Site	Roeselare
Belgium	502.373.1014 Boehringer Ingelheim Investigational Site	Seraing
Belgium	502.373.1002 Boehringer Ingelheim Investigational Site	Turnhout
Belgium	502.373.1010 Boehringer Ingelheim Investigational Site	Turnhout
Belgium	502.373.1025 Boehringer Ingelheim Investigational Site	Woluwé-Saint-Lambert
Brazil	502.373.405 Boehringer Ingelheim Investigational Site	Belo Horizonte
Brazil	502.373.412 Boehringer Ingelheim Investigational Site	Belo Horizonte
Brazil	502.373.426 Boehringer Ingelheim Investigational Site	Belo Horizonte
Brazil	502.373.418 Boehringer Ingelheim Investigational Site	Botucatu -
Brazil	502.373.407 Boehringer Ingelheim Investigational Site	Campinas
Brazil	502.373.419 Boehringer Ingelheim Investigational Site	Campinas
Brazil	502.373.425 Boehringer Ingelheim Investigational Site	Cerqueira César - São Paulo
Brazil	502.373.406 Boehringer Ingelheim Investigational Site	Curitiba
Brazil	502.373.411 Boehringer Ingelheim Investigational Site	Goiania
Brazil	502.373.403 Boehringer Ingelheim Investigational Site	Marília
Brazil	502.373.400 Boehringer Ingelheim Investigational Site	Pelotas
Brazil	502.373.416 Boehringer Ingelheim Investigational Site	Porto Alegre
Brazil	502.373.417 Boehringer Ingelheim Investigational Site	Porto Alegre
Brazil	502.373.415 Boehringer Ingelheim Investigational Site	Porto Alegre - Rs
Brazil	502.373.420 Boehringer Ingelheim Investigational Site	Ribeirao Preto
Brazil	502.373.414 Boehringer Ingelheim Investigational Site	Rio de Janeiro
Brazil	502.373.413 Boehringer Ingelheim Investigational Site	Rio de Janeiro - Rj
Brazil	502.373.409 Boehringer Ingelheim Investigational Site	Salvador
Brazil	502.373.410 Boehringer Ingelheim Investigational Site	Salvador
Brazil	502.373.404 Boehringer Ingelheim Investigational Site	Santa Catalina
Brazil	502.373.421 Boehringer Ingelheim Investigational Site	Sao Jose do Rio Preto
Brazil	502.373.422 Boehringer Ingelheim Investigational Site	Sao Paulo
Brazil	502.373.402 Boehringer Ingelheim Investigational Site	São Paulo
Brazil	502.373.408 Boehringer Ingelheim Investigational Site	São Paulo
Brazil	502.373.424 Boehringer Ingelheim Investigational Site	São Paulo
Brazil	502.373.423 Boehringer Ingelheim Investigational Site	Vila Clementino, São Paulo
Canada	502.373.0056 Antigonish Clinical Trials	Antigonish	Nova Scotia
Canada	502.373.0031 Brampton Research Associates	Brampton	Ontario
Canada	502.373.0001 C849 Division of Cardiology, Foothills Medical Centre	Calgary	Alberta
Canada	502.373.0071 Peter Lougheed Centre	Calgary	Alberta
Canada	502.373.0073 Alder Medical Centre	Campbell river	British Columbia
Canada	502.373.0062 Gain Medical Centre	Coquitlam	British Columbia
Canada	502.373.0020 CHA/University Hospital	Edmonton	Alberta
Canada	502.373.0081 Centre de recherche clinique, CUSE 3001	Fleurimont	Quebec
Canada	502.373.0076 Centre Hospitalier de Vallees de l'Outaouais Gatineau	Gatineau	Quebec
Canada	502.373.0045 Queen Elizabeth II HSC	Halifax	Nova Scotia
Canada	502.373.0011 St. Joseph's Hospital Cardiac Research	Hamilton	Ontario
Canada	502.373.0034 HGH McMaster Clinic	Hamilton	Ontario
Canada	502.373.0035 Hamilton Medical Research	Hamilton	Ontario
Canada	502.373.0064 Chedoke Hospital	Hamilton	Ontario
Canada	502.373.0082 3U4, McMaster University Medical Centre	Hamilton	Ontario
Canada	502.373.0085 HGH McMaster Clinic	Hamilton	Ontario
Canada	502.373.0046 Interior Clinical Research Consultants Ltd	Kelowna	British Columbia
Canada	502.373.0057 Centre De Recherche Clinique	Laval	Quebec
Canada	502.373.0033 Clinique de Cardiologie de Levis	Levis	Quebec
Canada	502.373.0024 London HSC - University Hospital	London	Ontario
Canada	502.373.0010 Recherche Invascor	Longueuil	Quebec
Canada	502.373.0013 Suite 170	Longueuil	Quebec
Canada	502.373.0014 Via Car Recherche Clinique Inc	Longueuil	Quebec
Canada	502.373.0015 C/O Peter Carmichael	Longueuil	Quebec
Canada	502.373.0016 Suite 170	Longueuil	Quebec
Canada	502.373.0017 Suite 170	Longueuil	Quebec
Canada	502.373.0086 Via Car Recherche Clinique Inc	Longueuil	Quebec
Canada	502.373.0030 Portage Clinical Studies	Manitoba
Canada	502.373.0044 Mississauga Clinical Research Centre	Mississauga	Ontario
Canada	502.373.0018 Montreal Heart Institute	Montreal	Quebec
Canada	502.373.0021 Medi - recherche Inc.	Montreal	Quebec
Canada	502.373.0022 CHUM - Hotel Dieu	Montreal	Quebec
Canada	502.373.0025 Hopital Maisonneuve Rosemont	Montreal	Quebec
Canada	502.373.0079 Jewish General Hospital	Montreal	Quebec
Canada	502.373.0038 New West Cardiac Research	New Westminster	British Columbia
Canada	502.373.0043 Fraser Clinical Trial Inc	New Westminster	Ontario
Canada	502.373.0032 New Market Cardiology Research Grp	Newmarket	Ontario
Canada	502.373.0037 Niagara Falls Medical Centre	Niagara Falls	Ontario
Canada	502.373.0048 Suite 100	North Vancouver	British Columbia
Canada	502.373.0054 Orleans Medical-Dental Centre	Orleans	Ontario
Canada	502.373.0058 Medical Sciences Building	Oshawa	Ontario
Canada	502.373.0063 Paradigm Clinical Trials	Oshawa	Ontario
Canada	502.373.0029 Riverside Professional Building	Ottawa	Ontario
Canada	502.373.0051 Merivale Cardiovascular Consultants	Ottawa	Ontario
Canada	502.373.0002 Penticton Regional Hospital	Penticton	British Columbia
Canada	502.373.0028 Hop. Du St. Sacrement	Quebec
Canada	502.373.0041 Recherches Clinicar Inc.	Quebec
Canada	502.373.0080 Polyclinique vasculaire Centre hospitalier universitaire de	Quebec
Canada	502.373.0084 CHA-Hopital de l'Efant-Jesus	Quebec
Canada	502.373.0040 Etobicok Cardiology	Rexdale	Ontario
Canada	502.373.0053 Mount Royal Clinic	Saskatoon	Saskatchewan
Canada	502.373.0055 Specialists - Internal Medicine	Saskatoon	Saskatchewan
Canada	502.373.0066 SDRI - University of Saskatchewan	Saskatoon	Saskatchewan
Canada	502.373.0067 SDRI - University of Saskatchewan	Saskatoon	Saskatchewan
Canada	502.373.0068 SDRI - University of Saskatchewan	Saskatoon	Saskatchewan
Canada	502.373.0070 SDRI - University of Saskatchewan	Saskatoon	Saskatchewan
Canada	502.373.0023 Group Health Centre - Clinical Trials	Sault Ste Marie	Ontario
Canada	502.373.0039 Scarborough Cardiology Research	Scarborough	Ontario
Canada	502.373.0027 Ctr Hospitalier Beauce Etchemin	St George de Beauce	Quebec
Canada	502.373.0005 Dr. Jeffrey Hiscock	ST John's	Newfoundland and Labrador
Canada	502.373.0006 The General Hospital	St. John's	Newfoundland and Labrador
Canada	502.373.0050 St. Pierre Medical Clinic	St. Pierre	Manitoba
Canada	502.373.0012 Hopital Laval - Institute Cardiologie de Quebec	Ste-Foy	Quebec
Canada	502.373.0007 Sudbury Cardiac Research	Sudbury	Ontario
Canada	502.373.0026 Centre hospitalier Pierre-Le Gardeur	Terrebonne	Quebec
Canada	502.373.0072 Chra	Thetford Mines	Quebec
Canada	502.373.0061 CLIKS Medical Research Corp	Thunder Bay	Ontario
Canada	502.373.0042 Sunnybrook & Woman's College Health Science Centre	Toronto	Ontario
Canada	502.373.0083 St. Michael's Hospital	Toronto	Ontario
Canada	502.373.0009 Vancouver Hospital	Vancouver	British Columbia
Canada	502.373.0003 Discovery Clinical Services Ltd	Victoria	British Columbia
Canada	502.373.0052 Dr. Bruce Lubelsky	Willowdale	Ontario
Canada	502.373.0008 Windsor Health Clinic	Windsor	Ontario
Canada	502.373.0077 Health Science Centre Diabetes Research Group	Winnipeg	Manitoba
China	502.373.0601 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0602 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0603 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0604 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0605 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0606 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0607 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0621 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0622 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0623 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0626 Boehringer Ingelheim Investigational Site	Beijing
China	502.373.0616 Boehringer Ingelheim Investigational Site	Changsha
China	502.373.0613 Boehringer Ingelheim Investigational Site	Chengdu
China	502.373.0625 Boehringer Ingelheim Investigational Site	Chengdu
China	502.373.0620 Boehringer Ingelheim Investigational Site	Guangzhou
China	502.373.0612 Boehringer Ingelheim Investigational Site	Harbin
China	502.373.0634 Boehringer Ingelheim Investigational Site	HeBei Province
China	502.373.0624 Boehringer Ingelheim Investigational Site	Henan Province
China	502.373.0627 Boehringer Ingelheim Investigational Site	Hubei Province
China	502.373.0614 Boehringer Ingelheim Investigational Site	Nanjing
China	502.373.0629 Boehringer Ingelheim Investigational Site	QingDao
China	502.373.0632 Boehringer Ingelheim Investigational Site	ShanDong Province
China	502.373.0633 Boehringer Ingelheim Investigational Site	ShanDong Province
China	502.373.0617 Boehringer Ingelheim Investigational Site	Shanghai
China	502.373.0618 Boehringer Ingelheim Investigational Site	Shanghai
China	502.373.0619 Boehringer Ingelheim Investigational Site	Shanghai
China	502.373.0628 Boehringer Ingelheim Investigational Site	Shen Yang
China	502.373.0611 Boehringer Ingelheim Investigational Site	Shijiazhuang
China	502.373.0615 Boehringer Ingelheim Investigational Site	Tianjin
China	502.373.0631 Boehringer Ingelheim Investigational Site	Tianjin
China	502.373.0630 Boehringer Ingelheim Investigational Site	Weizikeng
China	502.373.0608 Boehringer Ingelheim Investigational Site	Wuhan
China	502.373.0610 Boehringer Ingelheim Investigational Site	Zhenzhou
Czech Republic	502.373.1053 Boehringer Ingelheim Investigational Site	Brno
Czech Republic	502.373.1060 Boehringer Ingelheim Investigational Site	Havirov
Czech Republic	502.373.1055 Boehringer Ingelheim Investigational Site	Kladno
Czech Republic	502.373.1059 Boehringer Ingelheim Investigational Site	Mlada Boleslav
Czech Republic	502.373.1061 Boehringer Ingelheim Investigational Site	Plzen
Czech Republic	502.373.1057 Boehringer Ingelheim Investigational Site	Prague
Czech Republic	502.373.1051 Boehringer Ingelheim Investigational Site	Prague 5
Czech Republic	502.373.1062 Boehringer Ingelheim Investigational Site	Praha 2
Czech Republic	502.373.1056 Boehringer Ingelheim Investigational Site	Pribram 1
Czech Republic	502.373.1058 Boehringer Ingelheim Investigational Site	Usti nad Orlici
Denmark	502.373.1450 Boehringer Ingelheim Investigational Site	Aalborg
Denmark	502.373.1453 Boehringer Ingelheim Investigational Site	Aarhus C
Denmark	502.373.1455 Boehringer Ingelheim Investigational Site	Frederiksberg
Denmark	502.373.1459 Boehringer Ingelheim Investigational Site	Frederiksberg C
Denmark	502.373.1460 Boehringer Ingelheim Investigational Site	Helsingoer
Denmark	502.373.1458 Boehringer Ingelheim Investigational Site	Hilleroed
Denmark	502.373.1451 Boehringer Ingelheim Investigational Site	Holbaek
Denmark	502.373.1452 Boehringer Ingelheim Investigational Site	Hvidovre
Denmark	502.373.1461 Boehringer Ingelheim Investigational Site	Kjellerup
Denmark	502.373.1456 Boehringer Ingelheim Investigational Site	Randers
Denmark	502.373.1457 Boehringer Ingelheim Investigational Site	Slagelse
Denmark	502.373.1454 Boehringer Ingelheim Investigational Site	Svendborg
Finland	502.373.1486 Boehringer Ingelheim Investigational Site	Hämeenlinna
Finland	502.373.1470 Boehringer Ingelheim Investigational Site	Helsinki
Finland	502.373.1473 Boehringer Ingelheim Investigational Site	Helsinki
Finland	502.373.1479 Boehringer Ingelheim Investigational Site	Jyväskylä
Finland	502.373.1488 Boehringer Ingelheim Investigational Site	Kuopio
Finland	502.373.1481 Boehringer Ingelheim Investigational Site	Kuusankoski
Finland	502.373.1487 Boehringer Ingelheim Investigational Site	Liperi
Finland	502.373.1475 Boehringer Ingelheim Investigational Site	Oulun kaupunki
Finland	502.373.1471 Boehringer Ingelheim Investigational Site	Turku
Finland	502.373.1485 Boehringer Ingelheim Investigational Site	Vantaa
France	502.373.1093 Cabinet Médical	Albens
France	502.373.1090 Cabinet Médical	Beziers
France	502.373.1075 Cabinet Médical	Bourges
France	502.373.1091 Cabinet Médical	Broglie
France	502.373.1097 Cabinet Médical	Castelnaudary
France	502.373.1089 Cabinet Médical	Gemenos
France	502.373.1099 Cabinet Médical	Husseren Wesserlin
France	502.373.1094 Cabinet Médical	Hyeres
France	502.373.1078 Cabinet Médical des Tanneurs	L'Aigle
France	502.373.1096 Cabinet Médical	La Rochelle
France	502.373.1081 Cabinet Médical	Le Pradet
France	502.373.1083 Cabinet Médical	Murs Erigne
France	502.373.1084 Cabinet Médical	Nantes
France	502.373.1086 Cabinet Médical	Nantes
France	502.373.1080 Cabinet Médical	Niort
France	502.373.1095 Cabinet Médical	Ortez
France	502.373.1079 Cabinet Médical	Paris
France	502.373.1088 Cabinet Médical	Rennes
France	502.373.1098 Cabinet Médical	Rosiers d'Egletons
France	502.373.1085 Cabinet Médical	Saint Julien des Landes
France	502.373.1076 Cabinet Médical La Grande Ramée	Saint Martin dHyeres
France	502.373.1092 Cabinet Médical de St Pierre	Saint Pierre de Chandieu
France	502.373.1077 Cabinet Médical	Saint Romain sur Cher
France	502.373.1087 Cabinet Médical	Strasbourg
France	502.373.1082 Cabinet Médical	Tours
Germany	502.373.1164 Boehringer Ingelheim Investigational Site	Bad Lausick
Germany	502.373.1166 Boehringer Ingelheim Investigational Site	Bad Lauterberg
Germany	502.373.1138 Boehringer Ingelheim Investigational Site	Bad Mergentheim
Germany	502.373.1156 Boehringer Ingelheim Investigational Site	Berlin
Germany	502.373.1160 Boehringer Ingelheim Investigational Site	Berlin
Germany	502.373.1161 Boehringer Ingelheim Investigational Site	Berlin
Germany	502.373.1144 Boehringer Ingelheim Investigational Site	Bielefeld
Germany	502.373.1152 Boehringer Ingelheim Investigational Site	Dessau
Germany	502.373.1139 Boehringer Ingelheim Investigational Site	Dortmund
Germany	502.373.1159 Boehringer Ingelheim Investigational Site	Dortmund
Germany	502.373.1136 Boehringer Ingelheim Investigational Site	Dresden
Germany	502.373.1145 Boehringer Ingelheim Investigational Site	Eberswalde
Germany	502.373.1155 Boehringer Ingelheim Investigational Site	Erlangen
Germany	502.373.1157 Boehringer Ingelheim Investigational Site	Essen
Germany	502.373.1153 Boehringer Ingelheim Investigational Site	Haag
Germany	502.373.1148 Boehringer Ingelheim Investigational Site	Hamburg
Germany	502.373.1132 Boehringer Ingelheim Investigational Site	Heidelberg
Germany	502.373.1131 Boehringer Ingelheim Investigational Site	Homburg/Saar
Germany	502.373.1147 Boehringer Ingelheim Investigational Site	Karlsburg
Germany	502.373.1154 Boehringer Ingelheim Investigational Site	Kelkheim
Germany	502.373.1137 Boehringer Ingelheim Investigational Site	Köln
Germany	502.373.1142 Boehringer Ingelheim Investigational Site	Künzing
Germany	502.373.1165 Boehringer Ingelheim Investigational Site	Lübeck
Germany	502.373.1134 Boehringer Ingelheim Investigational Site	Mainz
Germany	502.373.1133 Boehringer Ingelheim Investigational Site	Melsungen
Germany	502.373.1146 Boehringer Ingelheim Investigational Site	München
Germany	502.373.1149 Boehringer Ingelheim Investigational Site	Offenbach am Main
Germany	502.373.1162 Boehringer Ingelheim Investigational Site	Riesa
Germany	502.373.1140 Boehringer Ingelheim Investigational Site	Rostock
Germany	502.373.1150 Boehringer Ingelheim Investigational Site	Sindelfingen
Germany	502.373.1163 Boehringer Ingelheim Investigational Site	Starnberg
Germany	502.373.1158 Boehringer Ingelheim Investigational Site	Stuttgart
Germany	502.373.1167 Boehringer Ingelheim Investigational Site	Timmendorfer Strand
Germany	502.373.1135 Boehringer Ingelheim Investigational Site	Wiesbaden
Germany	502.373.1141 Boehringer Ingelheim Investigational Site	Witten
Greece	502.373.1200 Boehringer Ingelheim Investigational Site	Athens
Greece	502.373.1203 Boehringer Ingelheim Investigational Site	Athens
Greece	502.373.1206 Boehringer Ingelheim Investigational Site	Athens
Greece	502.373.1207 Boehringer Ingelheim Investigational Site	Athens
Greece	502.373.1208 Boehringer Ingelheim Investigational Site	Athens
Greece	502.373.1214 Boehringer Ingelheim Investigational Site	Athens
Greece	502.373.1209 Boehringer Ingelheim Investigational Site	Elefsina
Greece	502.373.1211 Boehringer Ingelheim Investigational Site	Goudi/ Athens
Greece	502.373.1201 Boehringer Ingelheim Investigational Site	Ioannina
Greece	502.373.1210 Boehringer Ingelheim Investigational Site	Kavala,greece
Greece	502.373.1224 Boehringer Ingelheim Investigational Site	Korinthos
Greece	502.373.1202 Boehringer Ingelheim Investigational Site	Melissia, Athens
Greece	502.373.1205 Boehringer Ingelheim Investigational Site	Thessaloniki
Greece	502.373.1213 Boehringer Ingelheim Investigational Site	Thessaloniki
Greece	502.373.1204 Boehringer Ingelheim Investigational Site	Veria
Hong Kong	502.373.0676 Boehringer Ingelheim Investigational Site	Hong Kong
Hong Kong	502.373.0677 Boehringer Ingelheim Investigational Site	Hong Kong
Hong Kong	502.373.0680 Boehringer Ingelheim Investigational Site	Hong Kong
Hong Kong	502.373.0681 Boehringer Ingelheim Investigational Site	Hong Kong
Hong Kong	502.373.0685 Boehringer Ingelheim Investigational Site	Hong Kong
Hungary	502.373.1227 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1230 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1231 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1232 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1233 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1235 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1237 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1239 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1242 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1244 Boehringer Ingelheim Investigational Site	Budapest
Hungary	502.373.1236 Boehringer Ingelheim Investigational Site	Debrecen
Hungary	502.373.1240 Boehringer Ingelheim Investigational Site	Debrecen
Hungary	502.373.1228 Boehringer Ingelheim Investigational Site	Kecskemet
Hungary	502.373.1241 Boehringer Ingelheim Investigational Site	Nyiregyhaza
Hungary	502.373.1226 Boehringer Ingelheim Investigational Site	Pecs
Hungary	502.373.1229 Boehringer Ingelheim Investigational Site	Siofok
Hungary	502.373.1238 Boehringer Ingelheim Investigational Site	Szeged
Hungary	502.373.1225 Boehringer Ingelheim Investigational Site	Szekesfehervar
Hungary	502.373.1234 Boehringer Ingelheim Investigational Site	Tatabanya
Hungary	502.373.1243 Boehringer Ingelheim Investigational Site	Veszprem
Ireland	502.373.1717 Adelaide & Meath Hospitals	Dublin 24
Ireland	502.373.1714 Dept. of Clinical Pharmacology	Dublin 8
Ireland	502.373.1719 Pulmonary Function Laboratory	Dublin 9
Ireland	502.373.1720 Mallow General Hospital	Mallow
Italy	502.373.1257 Ospedale "Mazzoni"	Ascoli Piceno
Italy	502.373.1259 Ospedale di Bentivoglio	Bentivoglio (BO)
Italy	502.373.1255 Ospedale "S. Orsola Malpighi"	Bologna
Italy	502.373.1278 Ospedale Bellaria	Bologna
Italy	502.373.1275 A.O. Spedali Civili di Brescia -Univ. degli studi di Brescia	Brescia
Italy	502.373.1261 Ospedale Civile di Casarano	Casarano (LE)
Italy	502.373.1252 Azienda Ospedaliera di Caserta	Caserta
Italy	502.373.1254 Ospedale di Città della Pieve	Città della Pieve (PG)
Italy	502.373.1262 Arcispedale "S. Anna"	Ferrara
Italy	502.373.1250 Ospedale Civile "S. Polo"	Monfalcone (go)
Italy	502.373.1266 Azienda Universitaria Policlinico "Federico II"	Napoli
Italy	502.373.1267 Azienda Universitaria Policlinico II	Napoli
Italy	502.373.1269 Università Federico II	Napoli
Italy	502.373.1279 Asl Na 1	Napoli
Italy	502.373.1264 Presidio Ospedaliero "Villa Sofia"	Palermo
Italy	502.373.1265 IRCCS - Policlinico S. Matteo	Pavia
Italy	502.373.1251 Policlinico Monteluce	Perugia
Italy	502.373.1258 Ospedale "R. Silvestrini"	Perugia
Italy	502.373.1274 Ospedale "R. Silvestrini"	Perugia
Italy	502.373.1253 Istituto di Ricovero a Carattere Scientifico Neuromed- IRCCS	Pozzilli (IS)
Italy	502.373.1263 Policlinico Umberto I	Roma
Italy	502.373.1268 Ospedale "S. Spirito"	Roma
Italy	502.373.1270 Policlinico di Tor Vergata	Roma
Italy	502.373.1273 A.O. "S. Camillo de Lellis"	Roma
Italy	502.373.1260 Ospedale "N. Melli"	S. Pietro Vernotico (BR)
Italy	502.373.1256 Ospedale Civile SS. Annunziata - USL 1	Sassari
Italy	502.373.1277 A.S.O. "S. Giovanni Battista"	Torino
Italy	502.373.1272 Ospedale di Circolo di Varese	Varese
Italy	502.373.1271 Ospedale Civile	Venezia
Italy	502.373.1276 Ospedale Belcolle	Viterbo
Korea, Republic of	502.373.0763 Boehringer Ingelheim Investigational Site	Incheon
Korea, Republic of	502.373.0764 Boehringer Ingelheim Investigational Site	Kwang-ju
Korea, Republic of	502.373.0755 Boehringer Ingelheim Investigational Site	Pusan
Korea, Republic of	502.373.0750 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	502.373.0753 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	502.373.0756 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	502.373.0757 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	502.373.0760 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	502.373.0761 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	502.373.0754 Boehringer Ingelheim Investigational Site	Taegu
Malaysia	502.373.0736 Boehringer Ingelheim Investigational Site	Johor Baharu
Malaysia	502.373.0739 Boehringer Ingelheim Investigational Site	Kelantan
Malaysia	502.373.2707 Boehringer Ingelheim Investigational Site	Kelantan Darul Naim
Malaysia	502.373.0732 Boehringer Ingelheim Investigational Site	Kuala Lumpur
Malaysia	502.373.0734 Boehringer Ingelheim Investigational Site	Kuala Lumpur
Malaysia	502.373.0733 Boehringer Ingelheim Investigational Site	Penang
Malaysia	502.373.0731 Boehringer Ingelheim Investigational Site	Putrajaya
Malaysia	502.373.60001 Boehringer Ingelheim Investigational Site	Selangor
Mexico	502.373.0450 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	502.373.0451 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	502.373.0452 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	502.373.0459 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	502.373.0460 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	502.373.0461 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	502.373.0470 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	502.373.0457 Boehringer Ingelheim Investigational Site	Mexico
Mexico	502.373.0458 Boehringer Ingelheim Investigational Site	Mexico
Mexico	502.373.0454 Boehringer Ingelheim Investigational Site	Monterrey
Mexico	502.373.0453 Boehringer Ingelheim Investigational Site	Zapopan
Mexico	502.373.0456 Boehringer Ingelheim Investigational Site	Zapopan
Netherlands	502.373.1309 Boehringer Ingelheim Investigational Site	Amsterdam
Netherlands	502.373.1305 Boehringer Ingelheim Investigational Site	Beverwijk
Netherlands	502.373.1313 Boehringer Ingelheim Investigational Site	Den Bosch
Netherlands	502.373.1312 Boehringer Ingelheim Investigational Site	Den Haag
Netherlands	502.373.1302 Boehringer Ingelheim Investigational Site	Doetinchem
Netherlands	502.373.1304 Boehringer Ingelheim Investigational Site	Drachten
Netherlands	502.373.1301 Boehringer Ingelheim Investigational Site	Eindhoven
Netherlands	502.373.1318 Boehringer Ingelheim Investigational Site	Ermelo
Netherlands	502.373.1320 Boehringer Ingelheim Investigational Site	Ewijk
Netherlands	502.373.1310 Boehringer Ingelheim Investigational Site	Hengelo
Netherlands	502.373.1303 Boehringer Ingelheim Investigational Site	Hoorn
Netherlands	502.373.1322 Boehringer Ingelheim Investigational Site	Huizen
Netherlands	502.373.1300 Boehringer Ingelheim Investigational Site	Lichtenvoorde
Netherlands	502.373.1323 Boehringer Ingelheim Investigational Site	Losser
Netherlands	502.373.1307 Boehringer Ingelheim Investigational Site	Nieuwegein
Netherlands	502.373.1317 Boehringer Ingelheim Investigational Site	Rijswijk
Netherlands	502.373.1319 Boehringer Ingelheim Investigational Site	Roelofarendsveen
Netherlands	502.373.1308 Boehringer Ingelheim Investigational Site	Rotterdam
Netherlands	502.373.1321 Boehringer Ingelheim Investigational Site	Spijkenisse
Netherlands	502.373.1311 Boehringer Ingelheim Investigational Site	Stadskanaal
Netherlands	502.373.1314 Boehringer Ingelheim Investigational Site	Tilburg
Netherlands	502.373.1316 Boehringer Ingelheim Investigational Site	Utrecht
Netherlands	502.373.1315 Boehringer Ingelheim Investigational Site	Velp
New Zealand	502.373.0500 Boehringer Ingelheim Investigational Site	Auckland
New Zealand	502.373.0502 Boehringer Ingelheim Investigational Site	Auckland 3
New Zealand	502.373.0507 Boehringer Ingelheim Investigational Site	Christchurch
New Zealand	502.373.0504 Boehringer Ingelheim Investigational Site	Hamiton
New Zealand	502.373.0506 Boehringer Ingelheim Investigational Site	Hasting
New Zealand	502.373.0501 Middlemore Hospital	Otahuhu Auckland
New Zealand	502.373.0503 Boehringer Ingelheim Investigational Site	Takapuna Auckland
New Zealand	502.373.0505 Tauranga Study Centre	Tauranga
Norway	502.373.20003 Boehringer Ingelheim Investigational Site	Fevik
Norway	502.373.20004 Fana Hjertesenter	Nesttun
Norway	502.373.20001 Stavanger Universitetssykehus	Stavanger
Norway	502.373.20005 Sykehuset i Vestfold, Avd. Tønsberg	Tønsberg
Norway	502.373.20002 Tvedestrand Legesenter	Tvedestrand
Philippines	502.373.0702 De La Salle University Medical Center	Cavite
Philippines	502.373.0700 Philippine General Hospital	Manila
Philippines	502.373.0701 Manila Doctors Hospital, Room 3 Annex	Manila
Philippines	502.373.0705 The Medical City	Pasig City
Philippines	502.373.0703 Philippine Heart Center	Quezon City
Philippines	502.373.0704 National Kidney & Transplant Institute, Room 821	Quezon City
Poland	502.373.1354 Boehringer Ingelheim Investigational Site	Bydgoszcz
Poland	502.373.1366 Boehringer Ingelheim Investigational Site	Czestochowa
Poland	502.373.1368 Boehringer Ingelheim Investigational Site	Gdynia
Poland	502.373.1365 Boehringer Ingelheim Investigational Site	Gdynia Redlowo
Poland	502.373.1359 Boehringer Ingelheim Investigational Site	Grojec
Poland	502.373.1369 Boehringer Ingelheim Investigational Site	Grudziadz
Poland	502.373.1375 Boehringer Ingelheim Investigational Site	Inowroclaw
Poland	502.373.1360 Boehringer Ingelheim Investigational Site	Jaroslawiec
Poland	502.373.1372 Boehringer Ingelheim Investigational Site	Katowice
Poland	502.373.1376 Boehringer Ingelheim Investigational Site	Katowice
Poland	502.373.1361 Boehringer Ingelheim Investigational Site	Kielce
Poland	502.373.1358 Boehringer Ingelheim Investigational Site	Lodz
Poland	502.373.1364 Boehringer Ingelheim Investigational Site	Lubartow
Poland	502.373.1374 Boehringer Ingelheim Investigational Site	Lubin
Poland	502.373.1367 Boehringer Ingelheim Investigational Site	Nowy Sacz
Poland	502.373.1356 Boehringer Ingelheim Investigational Site	Piotrkow Trybunalski
Poland	502.373.1370 Boehringer Ingelheim Investigational Site	Poznan
Poland	502.373.1357 Boehringer Ingelheim Investigational Site	Ruda Slaska
Poland	502.373.1352 Boehringer Ingelheim Investigational Site	Skierniewice
Poland	502.373.1362 Boehringer Ingelheim Investigational Site	Tarnow
Poland	502.373.1355 Boehringer Ingelheim Investigational Site	Tomaszow Mazowiecki
Poland	502.373.1353 Boehringer Ingelheim Investigational Site	Torun
Poland	502.373.1351 Boehringer Ingelheim Investigational Site	Warsaw
Poland	502.373.1363 Boehringer Ingelheim Investigational Site	Warsaw
Poland	502.373.1373 Boehringer Ingelheim Investigational Site	Wegrow
Portugal	502.373.1402 Hospital Garcia de Orta	Almada
Portugal	502.373.1400 Hospital Fernando Fonseca	Amadora
Portugal	502.373.1411 Hospital de Santa Cruz	Carnaxide
Portugal	502.373.1408 Hospitais da Universidade de Coimbra	Coimbra
Portugal	502.373.1406 Hospital Distrital de Faro Geral	Faro
Portugal	502.373.1403 Hospital de Santa Marta	Lisboa
Portugal	502.373.1409 Hospital de Santa Maria	Lisboa
Portugal	502.373.1401 Unidade Local de Saúde de Matosinhos	Matosinhos
Portugal	502.373.1410 Hospital de Santo António	Porto
Portugal	502.373.1407 Centro Hospitalar vila Nova de Gaia	Vila Nova de Gaia
Puerto Rico	502.373.0215 Boehringer Ingelheim Investigational Site	Caguas
Puerto Rico	502.373.0267 Boehringer Ingelheim Investigational Site	Las Lomas
Puerto Rico	502.373.0190 Boehringer Ingelheim Investigational Site	Manati
Puerto Rico	502.373.0198 Boehringer Ingelheim Investigational Site	Orocovis
Puerto Rico	502.373.0262 Boehringer Ingelheim Investigational Site	Rio Piedras
Russian Federation	502.373.1425 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	502.373.1426 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	502.373.1427 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	502.373.1428 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	502.373.1429 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	502.373.1430 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	502.373.1433 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	502.373.1431 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	502.373.1432 Boehringer Ingelheim Investigational Site	St. Petersburg
Singapore	502.373.2706 Boehringer Ingelheim Investigational Site	Kuala Lumpur
Singapore	502.373.0725 Boehringer Ingelheim Investigational Site	Singapore
Singapore	502.373.0726 Boehringer Ingelheim Investigational Site	Singapore
Slovakia	502.373.1535 Boehringer Ingelheim Investigational Site	Bratislava
Slovakia	502.373.1529 Boehringer Ingelheim Investigational Site	Kosice
Slovakia	502.373.1540 Boehringer Ingelheim Investigational Site	Kosice
Slovakia	502.373.1538 Boehringer Ingelheim Investigational Site	Nitra
Slovakia	502.373.1545 Boehringer Ingelheim Investigational Site	Rimavska Sobota
South Africa	502.373.1553 Boehringer Ingelheim Investigational Site	Bellville
South Africa	502.373.1552 Boehringer Ingelheim Investigational Site	Bloemfontein
South Africa	502.373.1550 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	502.373.1561 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	502.373.1554 Boehringer Ingelheim Investigational Site	Congella
South Africa	502.373.1551 Boehringer Ingelheim Investigational Site	Durban
South Africa	502.373.1560 Boehringer Ingelheim Investigational Site	Fiachrdtpark, Bloemfontein
South Africa	502.373.1563 Boehringer Ingelheim Investigational Site	George East
South Africa	502.373.1555 Boehringer Ingelheim Investigational Site	Park Town West
South Africa	502.373.1559 Boehringer Ingelheim Investigational Site	Port Elizabeth
South Africa	502.373.1562 Boehringer Ingelheim Investigational Site	Port Elizabeth
South Africa	502.373.1558 Boehringer Ingelheim Investigational Site	Soweto
South Africa	502.373.1557 Boehringer Ingelheim Investigational Site	Sunninghill
South Africa	502.373.1564 Boehringer Ingelheim Investigational Site	Sunninghill
South Africa	502.373.1556 Boehringer Ingelheim Investigational Site	Vanderbijlpark
Spain	502.373.1582 Boehringer Ingelheim Investigational Site	Alcorcón (Madrid)
Spain	502.373.1601 Boehringer Ingelheim Investigational Site	Alicante
Spain	502.373.1586 Boehringer Ingelheim Investigational Site	Barcelona
Spain	502.373.1590 Boehringer Ingelheim Investigational Site	Barcelona
Spain	502.373.1597 Boehringer Ingelheim Investigational Site	Barcelona
Spain	502.373.1599 Boehringer Ingelheim Investigational Site	Barcelona
Spain	502.373.1595 Boehringer Ingelheim Investigational Site	Burjasot (Valencia)
Spain	502.373.1584 Boehringer Ingelheim Investigational Site	Granada
Spain	502.373.1585 Boehringer Ingelheim Investigational Site	Granada
Spain	502.373.1576 Boehringer Ingelheim Investigational Site	Madrid
Spain	502.373.1578 Boehringer Ingelheim Investigational Site	Madrid
Spain	502.373.1580 Boehringer Ingelheim Investigational Site	Madrid
Spain	502.373.1589 Boehringer Ingelheim Investigational Site	Madrid
Spain	502.373.1592 Boehringer Ingelheim Investigational Site	Madrid
Spain	502.373.1577 Boehringer Ingelheim Investigational Site	Málaga
Spain	502.373.1596 Boehringer Ingelheim Investigational Site	Málaga
Spain	502.373.1594 Boehringer Ingelheim Investigational Site	Murcia
Spain	502.373.1579 Boehringer Ingelheim Investigational Site	Santiago de Compostela
Spain	502.373.1593 Boehringer Ingelheim Investigational Site	Santiago de Compostela
Spain	502.373.1598 Boehringer Ingelheim Investigational Site	Santiago de Compostela
Spain	502.373.1583 Boehringer Ingelheim Investigational Site	Sevilla
Spain	502.373.1575 Boehringer Ingelheim Investigational Site	Valencia
Spain	502.373.1591 Boehringer Ingelheim Investigational Site	Valencia
Sweden	502.373.1504 Capio Lundby sjukhus	Göteborg
Sweden	502.373.1509 Hjärtsektionen / Med.kliniken	Göteborg
Sweden	502.373.1514 Hjärt/Kärlforskn.enheten	Göteborg
Sweden	502.373.1501 Hjaertmottagningen	Helsingborg
Sweden	502.373.1505 Jakobsbergs sjukhus	Järfälla
Sweden	502.373.1506 Hjärtmottagningen	Malmö
Sweden	502.373.1507 Kardiologiska kliniken	Malmö
Sweden	502.373.1508 Kolgahuset Läkargrupp	Malmö
Sweden	502.373.1502 Borgmästargaardens Läkarmottagning	Malmoe
Sweden	502.373.1511 Sjuntorps Vaardcentral	Sjuntorp
Sweden	502.373.1503 Källtorps Vaardcentral	Trollhättan
Sweden	502.373.1512 Vännäs Vaardcentral	Vännäs
Switzerland	502.373.1625 Boehringer Ingelheim Investigational Site	Basel
Switzerland	502.373.1632 Boehringer Ingelheim Investigational Site	Bellinzona
Switzerland	502.373.1634 Boehringer Ingelheim Investigational Site	Bern
Switzerland	502.373.1627 Boehringer Ingelheim Investigational Site	Biel/Bienne
Switzerland	502.373.1631 Boehringer Ingelheim Investigational Site	Chur
Switzerland	502.373.1633 Boehringer Ingelheim Investigational Site	Kreuzlingen
Switzerland	502.373.1639 Boehringer Ingelheim Investigational Site	Lausanne
Switzerland	502.373.1629 Boehringer Ingelheim Investigational Site	Lugano
Switzerland	502.373.1628 Boehringer Ingelheim Investigational Site	St. Gallen
Switzerland	502.373.1637 Boehringer Ingelheim Investigational Site	Zürich
Taiwan	502.373.0780 Boehringer Ingelheim Investigational Site	Changhua
Taiwan	502.373.0779 Boehringer Ingelheim Investigational Site	Chia-Yi
Taiwan	502.373.0783 Boehringer Ingelheim Investigational Site	Hualien
Taiwan	502.373.0776 Boehringer Ingelheim Investigational Site	Kaohsiung
Taiwan	502.373.0778 Boehringer Ingelheim Investigational Site	Kaohsiung
Taiwan	502.373.0775 Boehringer Ingelheim Investigational Site	Tainan
Taiwan	502.373.0777 Boehringer Ingelheim Investigational Site	Tainan
Taiwan	502.373.0781 Boehringer Ingelheim Investigational Site	Taipei
Taiwan	502.373.0782 Boehringer Ingelheim Investigational Site	Taipei
Thailand	502.373.0801 Boehringer Ingelheim Investigational Site	Bangkok
Thailand	502.373.0802 Boehringer Ingelheim Investigational Site	Bangkok
Thailand	502.373.0804 Boehringer Ingelheim Investigational Site	Bangkok
Thailand	502.373.0805 Boehringer Ingelheim Investigational Site	Bangkok
Thailand	502.373.0806 Boehringer Ingelheim Investigational Site	Bangkok
Thailand	502.373.0808 Boehringer Ingelheim Investigational Site	Bangkok
Thailand	502.373.0803 Boehringer Ingelheim Investigational Site	Khon Kaen
Thailand	502.373.0807 Boehringer Ingelheim Investigational Site	Nonthaburi
Turkey	502.373.1651 Cukurova Universitesi Tip Fakultesi	Adana
Turkey	502.373.1652 Cukurova Universitesi Tip Fakultesi	Adana
Turkey	502.373.1653 Ankara Hastanesi Endokrinoloji Bölümü	Ankara
Turkey	502.373.1656 Baskent Universitesi Tip Fakultesi	Ankara
Turkey	502.373.1659 Ankara Universitesi Tip Fakultesi	Ankara
Turkey	502.373.1654 Göztepe SSK Egitim ve Arastirma Hastanesi	Istanbul
Turkey	502.373.1655 Cerrahpasa Universitesi Tip Fakultesi	Istanbul
Turkey	502.373.1657 Haseki Hastanesi	Istanbul
Turkey	502.373.1658 Ege Universitesi Tip Fakultesi	Izmir
Turkey	502.373.1650 Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali	Kayseri
Ukraine	502.373.1730 Boehringer Ingelheim Investigational Site	Dnyepropetrovsk
Ukraine	502.373.1731 Boehringer Ingelheim Investigational Site	Dnyepropetrovsk
Ukraine	502.373.1728 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	502.373.1732 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	502.373.1733 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	502.373.1725 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	502.373.1726 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	502.373.1727 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	502.373.1729 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	502.373.1734 Boehringer Ingelheim Investigational Site	Kiev
United Arab Emirates	502.373.1680 Boehringer Ingelheim Investigational Site	Abu Dhabi
United Arab Emirates	502.373.1675 Boehringer Ingelheim Investigational Site	Dubai
United Arab Emirates	502.373.1679 Boehringer Ingelheim Investigational Site	Dubai
United Arab Emirates	502.373.1677 Boehringer Ingelheim Investigational Site	Sharjah
United Kingdom	502.373.1698 Boehringer Ingelheim Investigational Site	Aberdeen
United Kingdom	502.373.1706 Boehringer Ingelheim Investigational Site	Bathampton
United Kingdom	502.373.1690 Boehringer Ingelheim Investigational Site	Belfast
United Kingdom	502.373.1694 Boehringer Ingelheim Investigational Site	Birmingham
United Kingdom	502.373.1707 Boehringer Ingelheim Investigational Site	Brighton
United Kingdom	502.373.1703 Boehringer Ingelheim Investigational Site	Cardiff
United Kingdom	502.373.1709 Boehringer Ingelheim Investigational Site	Chichester
United Kingdom	502.373.1701 Boehringer Ingelheim Investigational Site	Derby
United Kingdom	502.373.1705 Boehringer Ingelheim Investigational Site	Gateshead
United Kingdom	502.373.1710 Boehringer Ingelheim Investigational Site	Glasgow
United Kingdom	502.373.1700 Boehringer Ingelheim Investigational Site	Kirkcaldy, Fife
United Kingdom	502.373.1691 Boehringer Ingelheim Investigational Site	Leeds
United Kingdom	502.373.1699 Boehringer Ingelheim Investigational Site	Leicester
United Kingdom	502.373.1702 Boehringer Ingelheim Investigational Site	Lincoln
United Kingdom	502.373.1697 Boehringer Ingelheim Investigational Site	Liverpool
United Kingdom	502.373.1695 Boehringer Ingelheim Investigational Site	London
United Kingdom	502.373.1693 Boehringer Ingelheim Investigational Site	Manchester
United Kingdom	502.373.1708 Boehringer Ingelheim Investigational Site	Portadown, County Atrim
United Kingdom	502.373.1692 Boehringer Ingelheim Investigational Site	Rugby
United Kingdom	502.373.1696 Boehringer Ingelheim Investigational Site	Sheffield
United Kingdom	502.373.1704 Boehringer Ingelheim Investigational Site	Stirling
United States	502.373.0256 Boehringer Ingelheim Investigational Site	Athens	Alabama
United States	502.373.0161 Boehringer Ingelheim Investigational Site	Augusta	Georgia
United States	502.373.0193 Boehringer Ingelheim Investigational Site	Augusta	Georgia
United States	502.373.0201 Boehringer Ingelheim Investigational Site	Augusta	Georgia
United States	502.373.0247 Boehringer Ingelheim Investigational Site	Baltimore	Maryland
United States	502.373.0209 Boehringer Ingelheim Investigational Site	Bentonville	Arkansas
United States	502.373.0181 Boehringer Ingelheim Investigational Site	Biloxi	Mississippi
United States	502.373.0251 Boehringer Ingelheim Investigational Site	Birmingham	Alabama
United States	502.373.0284 Boehringer Ingelheim Investigational Site	Boston	Massachusetts
United States	502.373.0226 Boehringer Ingelheim Investigational Site	Bridgeport	Connecticut
United States	502.373.0150 Boehringer Ingelheim Investigational Site	Bronx	New York
United States	502.373.0213 Boehringer Ingelheim Investigational Site	Brooklyn	New York
United States	502.373.0230 Boehringer Ingelheim Investigational Site	Buffalo	New York
United States	502.373.0244 Boehringer Ingelheim Investigational Site	Burbank	Illinois
United States	502.373.0249 Boehringer Ingelheim Investigational Site	Burke	Virginia
United States	502.373.0157 Boehringer Ingelheim Investigational Site	Camden	New Jersey
United States	502.373.0184 Boehringer Ingelheim Investigational Site	Charleston	South Carolina
United States	502.373.0272 Boehringer Ingelheim Investigational Site	Chicago	Illinois
United States	502.373.0155 Boehringer Ingelheim Investigational Site	Cincinnati	Ohio
United States	502.373.0164 Boehringer Ingelheim Investigational Site	Cleveland	Ohio
United States	502.373.0185 Boehringer Ingelheim Investigational Site	Cleveland	Mississippi
United States	502.373.0248 Boehringer Ingelheim Investigational Site	Columbia	South Carolina
United States	502.373.0173 Boehringer Ingelheim Investigational Site	Concord	California
United States	502.373.0223 Boehringer Ingelheim Investigational Site	Conyers	Georgia
United States	502.373.0172 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	502.373.0187 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	502.373.0219 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	502.373.0275 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	502.373.0168 Boehringer Ingelheim Investigational Site	Dayton	Ohio
United States	502.373.0270 Boehringer Ingelheim Investigational Site	Des Moines	Iowa
United States	502.373.0273 Boehringer Ingelheim Investigational Site	Durham	North Carolina
United States	502.373.0202 Boehringer Ingelheim Investigational Site	East Orange	New Jersey
United States	502.373.0265 Boehringer Ingelheim Investigational Site	Erie	Pennsylvania
United States	502.373.0222 Boehringer Ingelheim Investigational Site	Fargo	North Dakota
United States	502.373.0174 Boehringer Ingelheim Investigational Site	Farmington	Connecticut
United States	502.373.0221 Boehringer Ingelheim Investigational Site	Fort Worth	Texas
United States	502.373.0179 Boehringer Ingelheim Investigational Site	Gainesville	Florida
United States	502.373.0259 Boehringer Ingelheim Investigational Site	Guthrie	Oklahoma
United States	502.373.0266 Boehringer Ingelheim Investigational Site	Harbor City	California
United States	502.373.0206 Boehringer Ingelheim Investigational Site	Houston	Texas
United States	502.373.0234 Boehringer Ingelheim Investigational Site	Houston	Texas
United States	502.373.0280 Boehringer Ingelheim Investigational Site	Houston	Texas
United States	502.373.0254 Boehringer Ingelheim Investigational Site	Jackson	Mississippi
United States	502.373.0195 Boehringer Ingelheim Investigational Site	Kansas City	Missouri
United States	502.373.0288 Boehringer Ingelheim Investigational Site	Kingston	New York
United States	502.373.0283 Boehringer Ingelheim Investigational Site	Loma Linda	California
United States	502.373.0180 Boehringer Ingelheim Investigational Site	Los Angeles	California
United States	502.373.0159 Boehringer Ingelheim Investigational Site	Mansfield	Ohio
United States	502.373.0212 Boehringer Ingelheim Investigational Site	Milwaukee	Wisconsin
United States	502.373.0208 Boehringer Ingelheim Investigational Site	Minneapolis	Minnesota
United States	502.373.0232 Boehringer Ingelheim Investigational Site	Minneapolis	Minnesota
United States	502.373.0167 Boehringer Ingelheim Investigational Site	Monroe	Louisiana
United States	502.373.0238 Boehringer Ingelheim Investigational Site	New York	New York
United States	502.373.0252 Boehringer Ingelheim Investigational Site	New York	New York
United States	502.373.0286 Boehringer Ingelheim Investigational Site	New York	New York
United States	502.373.0191 Boehringer Ingelheim Investigational Site	Newark	New Jersey
United States	502.373.0169 Boehringer Ingelheim Investigational Site	North Las Vegas	Nevada
United States	502.373.0166 Boehringer Ingelheim Investigational Site	Northport	New York
United States	502.373.0154 Boehringer Ingelheim Investigational Site	Oklahoma City	Oklahoma
United States	502.373.0178 Boehringer Ingelheim Investigational Site	Oklahoma City	Ohio
United States	502.373.0217 Boehringer Ingelheim Investigational Site	Olympia Fields	Illinois
United States	502.373.0279 Boehringer Ingelheim Investigational Site	Omaha	Nebraska
United States	502.373.0183 Boehringer Ingelheim Investigational Site	Palm Harbor	Florida
United States	502.373.0240 Boehringer Ingelheim Investigational Site	Panama City	Florida
United States	502.373.0153 Boehringer Ingelheim Investigational Site	Philadelphia	Pennsylvania
United States	502.373.0182 Boehringer Ingelheim Investigational Site	Phoenix	Arizona
United States	502.373.0188 Boehringer Ingelheim Investigational Site	Phoenix	Arizona
United States	502.373.0203 Boehringer Ingelheim Investigational Site	Pocatello	Idaho
United States	502.373.0243 Boehringer Ingelheim Investigational Site	Portland	Oregon
United States	502.373.0156 Boehringer Ingelheim Investigational Site	Rochester	New York
United States	502.373.0264 Boehringer Ingelheim Investigational Site	Rochester	New York
United States	502.373.0175 Boehringer Ingelheim Investigational Site	Sacramento	California
United States	502.373.0165 Boehringer Ingelheim Investigational Site	San Diego	California
United States	502.373.0228 Boehringer Ingelheim Investigational Site	San Leandro	California
United States	502.373.0268 Boehringer Ingelheim Investigational Site	Sandersville	Georgia
United States	502.373.0245 Boehringer Ingelheim Investigational Site	Savannah	Georgia
United States	502.373.0227 Boehringer Ingelheim Investigational Site	Scarsdale	New York
United States	502.373.0281 Boehringer Ingelheim Investigational Site	Seattle	Washington
United States	502.373.0274 Boehringer Ingelheim Investigational Site	Sellersville	Pennsylvania
United States	502.373.0158 Boehringer Ingelheim Investigational Site	Shreveport	Louisiana
United States	502.373.0229 Boehringer Ingelheim Investigational Site	Springfield	Massachusetts
United States	502.373.0207 Boehringer Ingelheim Investigational Site	St. Louis	Missouri
United States	502.373.0239 Boehringer Ingelheim Investigational Site	St. Louis	Missouri
United States	502.373.0231 Boehringer Ingelheim Investigational Site	St. Paul	Minnesota
United States	502.373.0205 Boehringer Ingelheim Investigational Site	Sylmar	California
United States	502.373.0171 Boehringer Ingelheim Investigational Site	Tampa	Florida
United States	502.373.0199 Boehringer Ingelheim Investigational Site	Tucker	Georgia
United States	502.373.0189 Boehringer Ingelheim Investigational Site	Tucson	Arizona
United States	502.373.0152 Boehringer Ingelheim Investigational Site	Tulsa	Oklahoma
United States	502.373.0177 Boehringer Ingelheim Investigational Site	Tuscon	Arizona
United States	502.373.0162 Boehringer Ingelheim Investigational Site	Valdosta	Georgia
United States	502.373.0282 Boehringer Ingelheim Investigational Site	Vero Beach	Florida
United States	502.373.0258 Boehringer Ingelheim Investigational Site	Washington	District of Columbia
United States	502.373.0277 Boehringer Ingelheim Investigational Site	West Hills	California
United States	502.373.0163 Boehringer Ingelheim Investigational Site	Westfield	New York
United States	502.373.0214 Boehringer Ingelheim Investigational Site	Weston	Florida
United States	502.373.0271 Boehringer Ingelheim Investigational Site	Westwood	New Jersey
United States	502.373.0241 Boehringer Ingelheim Investigational Site	Williamsville	New York
United States	502.373.0261 Boehringer Ingelheim Investigational Site	Winston Salem	North Carolina
United States	502.373.0237 Boehringer Ingelheim Investigational Site	Wyandotte	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  China,  Czech Republic,  Denmark,  Finland,  France,  Germany,  Greece,  Hong Kong,  Hungary,  Ireland,  Italy,  Korea, Republic of,  Malaysia,  Mexico,  Netherlands,  New Zealand,  Norway,  Philippines,  Poland,  Portugal,  Puerto Rico,  Russian Federation,  Singapore,  Slovakia,  South Africa,  Spain,  Sweden,  Switzerland,  Taiwan,  Thailand,  Turkey,  Ukraine,  United Arab Emirates,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.	56 months	No
Primary	ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients	ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.; These renal outcomes were not adjudicated (apart from death).	56 months	No
Primary	TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.	56 months	No
Secondary	ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, non-fatal myocardial infarction or non-fatal stroke	56 months	No
Secondary	ONTARGET. Cardiovascular Death	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint cardiovascular death.	56 months	No
Secondary	ONTARGET. Non-fatal Myocardial Infarction	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint non-fatal myocardial infarction.	56 months	No
Secondary	ONTARGET. Non-fatal Stroke	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint non-fatal stroke.	56 months	No
Secondary	ONTARGET. Hospitalization for Congestive Heart Failure	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint hospitalization for congestive heart failure.	56 months	No
Secondary	ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients	Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.	56 months	No
Secondary	ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients	ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.	56 months	No
Secondary	ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients	Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) =300 mg/g Crea at baseline.	56 months	No
Secondary	ONTARGET. Doubling of Serum Creatinine	ONTARGET. Nephropathy subcategory: doubling of serum creatinine	56 months	No
Secondary	ONTARGET. Progression to ESRD	ONTARGET. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m².	56 months	No
Secondary	ONTARGET. New Microalbuminuria	ONTARGET. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as Urinary Albumin Creatinine Ratio =30 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <30 mg/g Crea at baseline.	56 months	No
Secondary	ONTARGET. New Macroalbuminuria	ONTARGET. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as Urinary Albumin Creatinine Ratio =300 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <300 mg/g Crea at baseline.	56 months	No
Secondary	ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria	ONTARGET. Nephropathy subcategory: Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria	56 months	No
Secondary	ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria	ONTARGET. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR =30 mg/g Crea at baseline.	56 months	No
Secondary	ONTARGET. Newly Diagnosed Congestive Heart Failure	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Congestive Heart failure.	56 months	No
Secondary	ONTARGET. Cardiovascular Revascularization Procedure	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).	56 months	No
Secondary	ONTARGET. Newly Diagnosed Diabetes	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.	56 months	No
Secondary	ONTARGET. Cognitive Decline	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.	56 months	No
Secondary	ONTARGET. New Onset of Atrial Fibrillation	The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of endpoint new onset of atrial fibrillation.	56 months	No
Secondary	TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.	56 months	No
Secondary	TRANSCEND. Cardiovascular Death	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint cardiovascular death.	56 months	No
Secondary	TRANSCEND. Non-fatal Myocardial Infarction	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint non-fatal myocardial infarction.	56 months	No
Secondary	TRANSCEND. Non-fatal Stroke	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).	56 months	No
Secondary	TRANSCEND. Hospitalization for Congestive Heart Failure	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).	56 months	No
Secondary	TRANSCEND. Doubling of Serum Creatinine	TRANSCEND. Nephropathy subcategory: doubling of serum creatinine	56 months	No
Secondary	TRANSCEND. Progression to ESRD	TRANSCEND. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73m²	56 months	No
Secondary	TRANSCEND. New Microalbuminuria	TRANSCEND. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as UACR =30 mg/g creatinine [Crea] in patients with a UACR <30 mg/g Crea at baseline	56 months	No
Secondary	TRANSCEND. New Macroalbuminuria	TRANSCEND. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as UACR =300 mg/g creatinine [Crea] in patients with a UACR <300 mg/g Crea at baseline	56 months	No
Secondary	TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria	TRANSCEND. Nephropathy subcategory: Combined endpoint of doubling serum creatinine, progression to ESRD, new microalbuminuria or new macroalbuminuria	56 months	No
Secondary	TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria	TRANSCEND. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR =30 mg/g Crea at baseline.	56 months	No
Secondary	TRANSCEND. New Onset of Atrial Fibrillation	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).	56 months	No
Secondary	TRANSCEND. Cognitive Decline	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.	56 months	No
Secondary	TRANSCEND. Newly Diagnosed Diabetes	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.	56 months	No
Secondary	TRANSCEND. Cardiovascular Revascularization Procedure	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).	56 months	No
Secondary	TRANSCEND. Newly Diagnosed Congestive Heart Failure	Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).	56 months	No

External Links

•   Link
•   Link
•   Link